Boehringer Ingelheim

OverviewSuggest Edit

Boehringer Ingelheim a global pharmaceutical company engaged in human pharmaceuticals, animal health, and biopharmaceuticals businesses. It focuses on researching medicines and offering therapies for diseases for which satisfactory treatment options are currently unavailable and provides the entire value chain, starting from research and development through the production and commercialization of its products. The company provides treatments for cardiovascular and metabolic diseases, oncology, diseases of the central nervous system, infectious diseases, as well as veterinary vaccines and medicines, and a variety of biopharmaceuticals.

TypePrivate
Founded1885
HQIngelheim am Rhein, DE
Websiteboehringer-ingelheim.com
Employee Ratings4.1
Overall CultureC+

Latest Updates

Employees (est.) (Dec 2019)51,015(+2%)
Job Openings752
Revenue (FY, 2019)€21.3 B(+9%)
Cybersecurity ratingBMore

Key People/Management at Boehringer Ingelheim

Christian Boehringer

Christian Boehringer

Chairman of the Shareholders’ Committee
Hubertus von Baumbach

Hubertus von Baumbach

Chairman of the Board of Managing Directors
Carinne Brouillon

Carinne Brouillon

Member of the Board of Managing Directors, Human Pharma Business Unit
Michel Pairet

Michel Pairet

Member of the Board of Managing Directors, Innovation Unit
Jean Scheftsik de Szolnok

Jean Scheftsik de Szolnok

Member of the Board of Managing Directors, Animal Health Business Unit
Michael Schmelmer

Michael Schmelmer

Member of the Board of Managing Directors, Finance & Group Functions
Show more

Boehringer Ingelheim Office Locations

Boehringer Ingelheim has offices in Ingelheim am Rhein, Duluth, Ridgefield, Algiers and in 71 other locations
Ingelheim am Rhein, DE (HQ)
Binger Str. 173
Algiers, DZ
Coopérative El Yasmine, 29 route du stade, Ouled Fayet
Munro, AR
piso 2, EAA, Cazadores de Coquimbo 2841
Macquarie Park, AU
Level 1/78 Waterloo Rd
Vienna, AT
Dr.-Boehringer-Gasse 5-11
Minsk, BY
V. Khoruzhej street 22, office 1402
Show all (76)

Boehringer Ingelheim Financials and Metrics

Summary Metrics

Founding Date

1885
Show all financial metrics

Boehringer Ingelheim Revenue

Embed Graph
View revenue for all periods
Boehringer Ingelheim's revenue was reported to be €21.27 b in FY, 2019 which is a 8.4% increase from the previous period.
EUR

Revenue (FY, 2019)

21.3b

Revenue growth (FY, 2018 - FY, 2019), %

8.4%

Gross profit (FY, 2019)

14.0b

Gross profit margin (FY, 2019), %

65.8%

Net income (FY, 2019)

2.7b

EBIT (FY, 2019)

3.8b

Cash (31-Dec-2019)

2.2b
EURFY, 2017FY, 2018FY, 2019

Revenue

21.2b19.6b21.3b

Revenue growth, %

15%(7%)8%

Cost of goods sold

7.6b7.3b7.3b

Gross profit

13.6b12.3b14.0b
EURFY, 2017FY, 2018FY, 2019

Cash

3.1b4.3b2.2b

Accounts Receivable

3.1b3.5b4.2b

Prepaid Expenses

334.0m377.0m313.0m

Inventories

3.1b3.3b3.6b
EURFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

1.8b(229.0m)2.1b2.7b

Depreciation and Amortization

620.0m963.0m1.1b1.2b

Inventories

(249.0m)305.0m(229.0m)(274.0m)

Accounts Payable

151.0m(60.0m)8.0m9.0m
Show all financial metrics

Boehringer Ingelheim Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Active Clinical Studies

500400400

Manufacturing Facilities (Human Pharmaceuticals)

191620

New Products

200300200

Projects in Pipeline

90
Show all operating metrics

Boehringer Ingelheim Acquisitions / Subsidiaries

Company NameDateDeal Size
NBE-TherapeuticsDecember 10, 2020€1.18 b
Labor Dr. Merk & KollegenDecember 09, 2020
Global Stem cell TechnologyJuly 27, 2020
Northern BiologicsMay 14, 2020
Amal TherapeuticsJuly 15, 2019€325 m
ICD TherapeuticsMarch 29, 2019
ViraTherapeuticsSeptember 13, 2018$245 m
Funxional TherapeuticsJuly 23, 2012
Actimis PharmaceuticalsJune 17, 2008$515 m
International Diagnostic TechnologyJanuary 01, 1978
Show more

Boehringer Ingelheim Revenue Breakdown

Embed Graph

Boehringer Ingelheim revenue breakdown by business segment: 21.2% from Animal Health, 73.5% from Human Pharmaceuticals and 5.3% from Other

Boehringer Ingelheim revenue breakdown by geographic segment: 23.6% from Asia/Australia/Africa, 29.9% from Europe and 46.5% from Americas

Show all human capital metrics

Boehringer Ingelheim Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Boehringer Ingelheim Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Boehringer Ingelheim Online and Social Media Presence

Embed Graph

Boehringer Ingelheim Company Culture

  • Overall Culture

    C+

    73/100

  • CEO Rating

    B

    77/100

  • Compensation

    D

    55/100

Learn more on Comparably

Boehringer Ingelheim News and Updates

Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks

LONDON, June 9, 2021 /PRNewswire/ -- Lifebit Biotech Ltd announces the beginning of a long-term partnership with Boehringer Ingelheim to utilise Natural Language Processing (NLP) and Artificial Intelligence (AI) for the detection and early reporting of global disease outbreaks using...

Novatek Requalified as an "Approved Supplier" for Boehringer Ingelheim Aseptic Manufacturing Facilities

MONTREAL, May 26, 2021 /PRNewswire/ -- Novatek Requalified as an approved supplier for Boehringer Ingelheim, a global leader in healthcare. Novatek regulatory compliant quality solutions is used at Boehringer Ingelheim for its human pharma, animal health and biopharmaceutical aseptic...

Global Anti-Asthmatics and COPD Drugs Market Report 2021 with Focus on COVID-19 Impacts - Major Players are Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca

Dublin, May 21, 2021 (GLOBE NEWSWIRE) -- The "Anti-Asthmatics and COPD Drugs Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering. Major players in the anti-asthmatics and chronic obstructive pulmonary disease (COPD) marke…

Greater Good Charities with Boehringer Ingelheim Animal Health, and The Animal Rescue Site to Launch Good Flights Program, Will Transport 1,000 Asymptomatic Heartworm-Positive Shelter Dogs Across State Lines into Care and New Adoptive Homes

Over 2,000 at-risk shelter dogs in Louisiana to be transported to the East Coast as part of the program’s new “Save a Heart” Initiative Over 2,000 at-risk shelter dogs in Louisiana to be transported to the East Coast as part of the program’s new “Save a Heart” Initiative
Show more

Boehringer Ingelheim Frequently Asked Questions

  • When was Boehringer Ingelheim founded?

    Boehringer Ingelheim was founded in 1885.

  • Who are Boehringer Ingelheim key executives?

    Boehringer Ingelheim's key executives are Christian Boehringer, Hubertus von Baumbach and Carinne Brouillon.

  • How many employees does Boehringer Ingelheim have?

    Boehringer Ingelheim has 51,015 employees.

  • What is Boehringer Ingelheim revenue?

    Latest Boehringer Ingelheim annual revenue is €21.3 b.

  • What is Boehringer Ingelheim revenue per employee?

    Latest Boehringer Ingelheim revenue per employee is €417 k.

  • Who are Boehringer Ingelheim competitors?

    Competitors of Boehringer Ingelheim include Daiichi Sankyo, Pfizer and Zoetis.

  • Where is Boehringer Ingelheim headquarters?

    Boehringer Ingelheim headquarters is located at Binger Str. 173, Ingelheim am Rhein.

  • Where are Boehringer Ingelheim offices?

    Boehringer Ingelheim has offices in Ingelheim am Rhein, Duluth, Ridgefield, Algiers and in 71 other locations.

  • How many offices does Boehringer Ingelheim have?

    Boehringer Ingelheim has 76 offices.